Login / Signup

The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials.

Tobias W KlausenHenrik GregersenNiels AbildgaardNiels Frost AndersenUlf Christian FrølundPeter GimsingCarsten HellebergAnnette Juul Vangsted
Published in: Leukemia (2018)
Keyphrases
  • newly diagnosed
  • phase iii
  • end stage renal disease
  • clinical trial
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • randomized controlled trial
  • double blind